Peritoneal cancer Trials in Chicago, United States
Conditions / Peritoneal cancer / Chicago, United States
Research into Peritoneal cancer spans multiple therapeutic approaches and trial phases.
10 total trials for this combination
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT01104675 | Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer | COMPLETED | PHASE2 |
| NCT05887609 | An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib | RECRUITING | PHASE2 |
| NCT02915523 | Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer | COMPLETED | PHASE1/PHASE2 |
| NCT00096993 | A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | COMPLETED | PHASE2 |
| NCT04209855 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression | COMPLETED | PHASE3 |
| NCT05445778 | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | RECRUITING | PHASE3 |
| NCT01767675 | Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | COMPLETED | PHASE2 |
| NCT01493505 | TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer | TERMINATED | PHASE3 |
| NCT00669422 | ChemoFx® PRO - A Post-Market Data Collection Study | TERMINATED | — |
| NCT02657889 | Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer | COMPLETED | PHASE1/PHASE2 |